Shots:
Coherus will present the P-II trial data of casdozokitug (10mg/kg; IV; Q3W) + Tecentriq (1200mg) + Avastin (15mg/kg) vs PBO for 1L LA/M HCC patients (n=30), in both viral & non-viral diseases, at ASCO GI 2025
Study (as of Sep 2024) met its 1EP of safety & all 2EPs depicting 38% ORR (5…
